Acer Therapeutics Inc (NASDAQ:ACER) – Analysts at William Blair upped their FY2020 earnings estimates for shares of Acer Therapeutics in a note issued to investors on Thursday. William Blair analyst T. Lugo now expects that the biopharmaceutical company will earn $0.65 per share for the year, up from their previous estimate of $0.60. William Blair has a “Outperform” rating on the stock.
Acer Therapeutics (NASDAQ:ACER) last posted its earnings results on Wednesday, March 7th. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.53) by ($0.10).
Acer Therapeutics (NASDAQ:ACER) opened at $19.14 on Friday. The firm has a market capitalization of $137.95, a PE ratio of -4.92 and a beta of 2.54. Acer Therapeutics has a twelve month low of $5.70 and a twelve month high of $22.63.
Hedge funds and other institutional investors have recently modified their holdings of the company. Ardsley Advisory Partners purchased a new position in shares of Acer Therapeutics during the fourth quarter worth about $212,000. Stonepine Capital Management LLC purchased a new position in shares of Acer Therapeutics during the fourth quarter worth about $1,385,000. J. Goldman & Co LP purchased a new position in shares of Acer Therapeutics during the fourth quarter worth about $1,496,000. Finally, Perceptive Advisors LLC purchased a new position in shares of Acer Therapeutics during the fourth quarter worth about $2,091,000. 7.54% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION WARNING: This report was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this report on another publication, it was illegally copied and reposted in violation of United States & international trademark & copyright laws. The legal version of this report can be viewed at https://www.tickerreport.com/banking-finance/3252995/acer-therapeutics-inc-to-post-fy2020-earnings-of-0-65-per-share-william-blair-forecasts-acer.html.
Acer Therapeutics Company Profile
Acer Therapeutics Inc, formerly Opexa Therapeutics, Inc, is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001.
Receive News & Ratings for Acer Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acer Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.